Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
Launched by INSTITUT PAOLI-CALMETTES · Jul 11, 2018
Trial Information
Current as of July 24, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial is studying how certain factors in the immune system might help predict how well patients with advanced cancer respond to a type of treatment called Immune Checkpoint Blockade (ICB). ICB is a newer approach in cancer treatment that helps the body’s immune system fight cancer. However, not everyone responds to this treatment, and researchers want to understand why. To do this, they will collect blood samples and optional tumor samples from patients who are receiving ICB for conditions like lung cancer or lymphoma. The goal is to see if changes in specific immune cells and substances in the blood can predict how effective the treatment will be.
To participate in this study, individuals must be at least 18 years old, have been diagnosed with a locally advanced or metastatic solid tumor or lymphoma, and be receiving ICB treatment. They also need to provide informed consent and be affiliated with the French Social Security system. Participants can expect to provide blood samples at different points during their treatment, and optional tumor samples, to help researchers gather important information. It's important to note that pregnant or breastfeeding women, as well as individuals who cannot give consent or comply with follow-up visits, are not eligible for this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with Immune check blockade
- • Signed informed consent
- • Affiliated to(or beneficiary of) the French Social Security
- Exclusion Criteria:
- • Pregnant or breastfeeding woman or woman who does not apply effective contraception
- • Emergency
- • Vulnerable person or unable to provide informed consent
- • Emergency
- • Person unable to comply with required study follow up
- • Contraindication to the study procedure
About Institut Paoli Calmettes
Institut Paoli-Calmettes (IPC) is a leading cancer research and treatment center located in Marseille, France, dedicated to advancing oncology through innovative clinical trials and comprehensive patient care. With a multidisciplinary approach, IPC integrates cutting-edge research, education, and clinical services to enhance cancer prevention, diagnosis, and treatment. The institute is committed to fostering collaboration among researchers, healthcare professionals, and patients, aiming to translate scientific discoveries into effective therapeutic strategies. As a recognized institution in the field of oncology, IPC plays a pivotal role in shaping the future of cancer care and improving patient outcomes through rigorous and ethical clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marseille, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials